Source:http://linkedlifedata.com/resource/pubmed/id/17142049
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-1-8
|
pubmed:abstractText |
N-Allylation (-CH(2)-CHCH(2)) of [Dmt(1)]endomorphins yielded the following: (i) [N-allyl-Dmt(1)]endomorphin-2 (Dmt=2',6'-dimethyl-l-tyrosine) (12) and [N-allyl-Dmt(1)]endomorphin-1 (15) (K(i)mu=0.45 and 0.26nM, respectively) became mu-antagonists (pA(2)=8.59 and 8.18, respectively) with weak delta-antagonism (pA(2)=6.32 and 7.32, respectively); (ii) intracerebroventricularly administered 12 inhibited morphine-induced CNS-mediated antinociception in mice [AD(50) (0.148ng/mouse) was 16-fold more potent than naloxone], but not spinal antinociception, and (iii) 15 reversed the alcohol-elevated frequency in spontaneous inhibitory post-synaptic currents (IPSC) in hippocampal CA1 pyramidal cells in rat brain slices (P=0.0055). Similarly, N-allylation of the potent mu-opioidmimetic agonists, 1,6-bis-[H-Dmt-NH]-hexane and 3,6-bis-[Dmt-NH-propyl]-2(1H)-pyrazinone, converted them into mu-antagonists (pA(2)=7.23 and 7.17 for the N-allyl-derivatives 17 and 19, respectively), and exhibited weak delta-antagonism. Thus, N-allylation of Dmt containing opioid peptides or opioidmimetics continues to provide a facile means to convert selective mu-opioid agonists into potent mu-opioid antagonists.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0968-0896
|
pubmed:author |
pubmed-author:AmboAkihiroA,
pubmed-author:BryantSharon DSD,
pubmed-author:JinsmaaYundenY,
pubmed-author:LazarusLawrence HLH,
pubmed-author:LiQiangQ,
pubmed-author:LiTingyouT,
pubmed-author:MarczakEwaE,
pubmed-author:MiyazakiAnnaA,
pubmed-author:NedachiMasahiroM,
pubmed-author:OkadaYoshioY,
pubmed-author:SasakiYusukeY,
pubmed-author:SwartzwelderH ScottHS,
pubmed-author:TsudaYukoY
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1237-51
|
pubmed:dateRevised |
2007-12-3
|
pubmed:meshHeading |
pubmed-meshheading:17142049-Alkylation,
pubmed-meshheading:17142049-Analgesics, Opioid,
pubmed-meshheading:17142049-Animals,
pubmed-meshheading:17142049-Brain,
pubmed-meshheading:17142049-Disease Models, Animal,
pubmed-meshheading:17142049-Guinea Pigs,
pubmed-meshheading:17142049-Male,
pubmed-meshheading:17142049-Mice,
pubmed-meshheading:17142049-Morphine,
pubmed-meshheading:17142049-Pain,
pubmed-meshheading:17142049-Rats,
pubmed-meshheading:17142049-Receptors, Opioid, mu,
pubmed-meshheading:17142049-Structure-Activity Relationship,
pubmed-meshheading:17142049-Synaptosomes,
pubmed-meshheading:17142049-Vas Deferens
|
pubmed:year |
2007
|
pubmed:articleTitle |
Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists.
|
pubmed:affiliation |
The Graduate School of Food and Medicinal Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural,
Research Support, N.I.H., Intramural
|